Option chain shows key data for Mira Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mira Pharmaceuticals.

Mira Pharmaceuticals (NASDAQ:MIRA) Stock, Option Chain

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

mira

Biotech

News

Health Care

Movers

General

MIRA

MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief.

MIRA Pharmaceuticals&#39; Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

Screenshot 2024-10-02 at 5.44.40 PM

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here&#39;s what you need to know.

Why Mira Shares Are Trading Higher Today

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) reported quarterly earnings of $0.57 per share. This is a 32.51 percent decrease over earnings of $0.85 per share from the same period last year. The company reported $210.77 million in sales this quarter. This is a 17.32 percent increase over sales of $179.66 million the same period last year.

Earnings

Yiren Digital Q3 2024 EPS $0.57 Down From $0.85 YoY, Sales $210.77M Up From $179.66M YoY

The solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM Platform with high accuracy and efficiency.

SOPH

SOPHiA GENETICS Announced The Global Launch Of MSK-impact Powered With Sophia DDM From The Association For Molecular Pathology Annual Meeting

Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) reported quarterly losses of $(1.12) per share. This is a 12.5 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $2.06 billion which beat the analyst consensus estimate of $1.91 billion by 7.98 percent. This is a 12.80 percent increase over sales of $1.82 billion the same period last year.

BZUN

Baozun Q3 2024 GAAP EPS RMB(1.12) Up From RMB(1.28) YoY, Sales RMB2.06B Beat RMB1.91B Estimate

Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) reported quarterly losses of $(0.86) per share. This is a 10650 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $12.35 million in sales this quarter. This is a 37.92 percent decrease over sales of $19.90 million the same period last year.

Yunji Q3 EPS $(0.86) Down From $(0.01) YoY, Sales $12.35M Down From $19.90M YoY

Subsea 7 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SUBCY#OTC">SUBCY</a>) reported quarterly earnings of $0.31 per share. This is a 181.82 percent increase over earnings of $0.11 per share from the same period last year. The company reported $1.83 billion in sales this quarter. This is a 16.22 percent increase over sales of $1.58 billion the same period last year.

SUBCY

Subsea 7 Q3 EPS $0.31 Up From $0.11 YoY, Sales $1.83B Up From $1.58B YoY

<ul>
<li>In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310's potential to deliver localized therapeutic effects while minimizing systemic exposure. Additionally, all patients tolerated LP-310 without significant adverse reactions.</li>
<li>Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to advance to the next stage of the trial, which will evaluate a higher dose of 0.5 mg of LP-310.</li>
</ul>

LIPO

Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025

KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.57 by 2.55 percent. The company reported quarterly sales of $22.58 billion which missed the analyst consensus estimate of $23.46 billion by 3.74 percent. This is a 825.16 percent increase over sales of $2.44 billion the same period last year.

BEKE

KE Holdings Q3 2024 Adj EPADS RMB1.53 Misses RMB1.57 Estimate, Sales RMB22.58B Miss RMB23.46B Estimate

TD Cowen analyst Andrew Charles reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $50 price target.

Price Target

Reiteration

Analyst Ratings

JACK

TD Cowen Reiterates Hold on Jack In The Box, Maintains $50 Price Target

Needham analyst Bernie McTernan maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $200 to $235.

Needham Maintains Buy on Wix.com, Raises Price Target to $235

Delta Air Lines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NASDAQ">DAL</a>) CEO Ed Bastian has suggested that President-elect Donald Trump&#8216;s administration could provide a &#8220;breath of fresh air&#8221; for the airline industry, criticizing what he perceives as government &#8220;overreach&#8221; during President Joe Biden&#8216;s era.
What Happened: Speaking ahead of the company&#8217;s investor day, Bastian signaled potential regulatory changes that could significantly impact the aviation sector, <a href="https://apnews.com/article/delta-airlines-trump-biden-regulation-c4393d5f763d95c8286d4069563032dc#">reported</a> the Associated Press on Thursday.
The airline executive&#8217;s comments reflect a broader sentiment among industry leaders who anticipate a more business-friendly regulatory environment. 
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) CEO Robert Jordan similarly expressed hope for a Department of Transportation that might be &#8220;less aggressive&#8221; in rule-making, highlighting growing frustration with current consumer protection regulations.
See Also: <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">Bitcoin Hits $95K For The First Time Ever, Ethereum, Dogecoin Flat As Trump&#8217;s Crypto Policy Takes Shape</a>
Delta&#8217;s financial performance provides context for these expectations. The airline reported a robust $2.6 billion profit in the first nine months of 2024, with projected fourth-quarter adjusted profit between $1.60 and $1.85 per share. The company expects 2025 revenue growth in mid-single digits, positioning itself strongly amid potential regulatory shifts.
Why It Matters: Wall Street appears cautiously optimistic about <a href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector">the airline sector&#8217;s future</a>. Goldman Sachs has resumed coverage of major airlines, providing Delta with a &#8220;Buy&#8221; rating and an $83 price target. Analysts expect continued supply constraints through 2025, with a focus on airlines&#8217; ability to adapt to changing market conditions.
The potential appointment of Sean Duffy as Transportation Secretary could herald broader changes across the transportation sector. Industry <a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads">observers speculate about the potential streamlining of regulations</a>, enhanced infrastructure focus, and possible modifications to electric vehicle and autonomous driving policies.
Price Action: Delta Air Lines closed at $63.64 on Wednesday, down 1.71% for the day. In pre-market trading, the stock was down 0.5% at the time of writing. Year to date, the stock has surged by 57.33%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/42044634/653125">Dave Ramsey Recalls The Day American Express Called His Wife, Asking Why Stay &#8216;With A Man That Won&#8217;t Pay His Bills.&#8217; Here&#8217;s What He Did Next</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

Delta Chief Says Trump Could Be A 'Breath Of Fresh Air' For Aviation Industry

William Blair analyst Dylan Carden downgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Outperform to Market Perform.

Downgrades

ULTA

William Blair Downgrades Ulta Beauty to Market Perform

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) released their September quarter results just a day apart. Target&#8217;s management highlighted that its customers were most active during sales and promotional events, while Walmart&#8217;s leadership attributed 75% of its market share growth to households earning six-figure incomes.
Target&#8217;s executive vice president and chief commercial officer company Rick Gomez said that their consumers &#8220;know there are deals to be found, they&#8217;re willing to wait for sales and willing to search across multiple retailers.&#8221; While the latter&#8217;s chief executive officer, Doug McMillon attributed <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">75% of their market share gains</a> to "households earning more than $100,000."
Also read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart Market Share Surges As Six-Figure Income Households Drive 75% Of Growth In Q3: &#8216;People Come To Us To Shop As A Primary Destination&#8217;</a>
What Happened: Gomez highlighted that Target&#8217;s consumers were looking for promotions with an example. &#8220;Our Target Circle week this quarter was one of our biggest yet. However, we saw a more pronounced sales dip both the week before and the week after the event, showing just how planful consumers are in seeking out promotions when they shop.&#8221;
&#8220;Similarly, we saw consumers lean into everyday essential stock-up promotions throughout the quarter to further stretch their monthly budgets. We saw a strong reaction to promotions throughout the quarter,&#8221; he added.
On the flip side, John David Rainey the chief financial officer of Walmart re-affirmed his CEO&#8217;s view and said, &#8220;we're seeing higher engagement across income cohorts with upper-income households continuing to account for the majority of our share gains.&#8221;
Why It Matters: Shares of Target Corporation plunged by 21.41% to close at $121.72 apiece, on Wednesday, as compared to a 0.16% advance in the NYSE Composite Index. <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target&#8217;s third-quarter</a> adjusted earnings per share of $1.85, missed the street view of $2.30. Quarterly total revenue of $25.67 billion (+1.1% year over year) missed the analyst consensus estimate of $25.90 billion.
Brian Cornell, chair and chief executive officer of Target said, "We encountered some unique challenges and cost pressures that impacted our bottom-line performance.&#8221; The third-quarter gross margin rate decreased by 0.2 percentage points to 27.2%.
Also read: <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks</a>
On Tuesday, <a href="https://www.benzinga.com/pressreleases/24/11/b42058916/walmart-reports-strong-revenue-growth-of-5-5-with-operating-income-growing-faster-at-8-2">Walmart&#8217;s third-quarter results</a> beat estimates and the fiscal 2025 guidance was raised. Its shares rose 3% on Tuesday, while it was further up by 0.67% to $87.18 apiece as per Wednesday&#8217;s close.
Walmart&#8217;s ales were at $169.59 billion, up 5.5% year over year or 6.2% (at constant currency), beating the consensus of $167.72 billion. The gross margin rate was up 21 bps to 24.2% aided by improvement in the Walmart U.S. Operating income was up by $0.5 billion or 8.2% year over year at $6.7 billion.
Price Action: On a year-to-date basis, Walmart has surged by 64.19%, while Target is down by 14.94%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The NYSE Composite Index was up 17.26% in the same period. In Thursday&#8217;s premarket, TGT shares were up 0.5%. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="272" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png" alt="" class="wp-image-658433" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-300x80.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-768x204.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1536x408.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT.png 1741w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Flickr/ Mike Mozart

Earnings Beats

Earnings Misses

Target Says Shoppers Wait For 'Deals' A Day After Rival Walmart Credits Market Gains To Wealthy Households: TGT Edges Up Marginally In Thursday Premarket

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintains the price target from $4 to $4.

Upgrades

SAGE

RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4

Piper Sandler analyst Brent Bracelin reiterates Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $165 to $185.

SNOW

Piper Sandler Reiterates Overweight on Snowflake, Raises Price Target to $185

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) new vehicle registrations in the EU are continuing to drop, <a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown">threatening the company&#8217;s global EV delivery target</a> for the year.
What Happened: Tesla had 11,088 vehicle registrations in the European Union in October, marking a drop of 21% from the corresponding period last year, according to data from the European Automobile Manufacturers' Association (ACEA). 
This is despite battery electric vehicle registrations rising 2.4% in the EU last month to 124,907 units on the back of growing popularity in Denmark and the Netherlands. 
Tesla had 192,661 new vehicle registrations in the EU from January through the end of October, marking a drop of over 11% year-on-year. 
For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an ambitious target.
Why It Matters: In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
According to Tesla researcher Troy Teslike, the low sales in Europe are likely to impact Tesla&#8217;s aim to prevent a drop in yearly deliveries. 
&#8220;Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are down too,&#8221; <a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher">Teslike said</a> in a post on X earlier this week.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are… <a href="https://t.co/fflyf175xp">https://t.co/fflyf175xp</a>
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1858430634315943990?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Tesla stock fell 1.2% on Wednesday to close at $342.03, and declined over 1% in premarket trading on Thursday. Year-to-date, the stock is up 37.7%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways" target="_blank" rel="noreferrer noopener">Jim Cramer Thinks Trump's Plans For Robotaxis Are ‘Fanciful,' But He Is Still Bullish On Tesla Stock: ‘The Musk Premium Will Work Its Magic In Other Ways'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target

Macquarie analyst Austin Yun upgrades Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) from Underperform to Neutral and announces $13.5 price target.

Macquarie Upgrades Piedmont Lithium to Neutral, Announces $13.5 Price Target

<ul>
<li>Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029.&nbsp;</li>
<li>The company remains on track to deliver core operating income margin1 of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements.</li>
<li>"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms. Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Vas Narasimhan, CEO of Novartis. "Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029. Taken together, we remain confident in our focused strategy and ability to deliver sustainable value creation for shareholders."</li>
</ul>

Large Cap

Guidance

Novartis Upgrades Its Mid-term Guidance. Previous Guidance For +5% Sales CAGR 2023-2028 Was Upgraded To +6%, Driven By Strong Momentum Of In-market Growth Drivers And Upcoming Launches, Most Of Which Have Expected US Exclusivity In 2030's Or Beyond

HSBC analyst Carlos Gomez-Lopez initiates coverage on Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Buy rating and announces Price Target of $33.

Initiation

HSBC Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $33

The Offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company estimates that the net proceeds from the sale of the Notes, after deducting initial purchaser discounts but before deducting the other estimated expenses of the offering, will be approximately US$124.2 million (or approximately US$143.5 million if the initial purchasers exercise their option to purchase additional Notes in full). The Company intends to use the net proceeds from the Offering (including any net proceeds from the sale of any additional Notes that may be sold should the initial purchasers exercise their option to purchase additional Notes) for the construction of copper-gold mining projects outside of China, for the exploration and development of other projects and for working capital.

Silvercorp Metals Prices $130M 4.75% Convertible Senior Notes Due 2029

Investment supports continued expansion of AI and business intelligence capabilities for over 70,000 hospitality properties globally
Lighthouse, the leading commercial intelligence platform for the travel &amp; hospitality industry, today announced an approximately $370 million growth investment led by global investment firm, KKR. This investment accelerates Lighthouse's mission to reimagine commercial strategy for the $15 billion travel &amp; hospitality technology market. Proceeds from the investment will be used to drive continued product innovation across Lighthouse's platform, strategic acquisitions, and global expansion efforts.

KKR Backs Lighthouse With $370M To Redefine Hospitality Market Strategy With AI Tools

An update from MIRA Pharmaceuticals, Inc. (MIRA) is now available. MIRA Pharmaceuticals has approved a significant amendment to CEO Erez Aminov's e...

MIRA Pharmaceuticals Enhances CEO's Compensation Package

The latest update is out from MIRA Pharmaceuticals, Inc. (MIRA). MIRA Pharmaceuticals has revised its employment agreement with CFO Michelle Yanez,...

MIRA Pharmaceuticals Adjusts CFO Salary, Sets Annual Meeting

MIRA stock rallies 154% on preclinical results for ketamine drug

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MIRA Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is seeing massive gains on Monday after the pre-clinical-stage pharmaceutical company released data from its pre-clinical study of Ketamir-2.



Ketamir-2. is MIRA Pharmaceuticals&rsquo; novel oral ketamine analog. It&rsquo;s being studied as a potential <a href="https://finance.yahoo.com/news/mira-pharmaceuticals-reveals-preclinical-success-120000778.html">treatment for neurological and neuropsychiatric disorders</a>. That includes depression, treatment-resistant depression and post-traumatic stress disorder (PTSD).



Here&rsquo;s what MIRA Pharmaceuticals chairman and CEO Erez Aminov said about the new data.




&ldquo;Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families. Importantly, we are seeing a drumbeat of promising data this year that we hope will allow us to file an IND and begin to test our theories about Ketamir-2 in actual patients in the near term.&rdquo;




<h2>What This Means for MIRA Stock</h2>



MIRA stock could benefit greatly if the company is able to move forward with its IND plans. The company&rsquo;s shares are already gaining today with more than 116 million shares traded. For the record, its daily average trading volume is about 654,000 shares.



MIRA Stock is up 318.1% as of Monday afternoon.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news investors need to know about on Monday! Among that is what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Reddit&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/">RDDT</a>) and Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>) stock moving today. All of that info is good to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/nio-stock-alert-more-details-emerge-about-upcoming-nio-day-2024/">NIO Stock Alert: More Details Emerge About Upcoming Nio Day 2024</a></li>



<li><a href="https://investorplace.com/2024/07/rddt-stock-alert-reddit-nabs-new-deals-with-nfl-nba/">RDDT Stock Alert: Reddit Nabs New Deals with NFL, NBA</a></li>



<li><a href="https://investorplace.com/2024/07/sava-stock-alert-cassava-sciences-pops-on-late-stage-trial-update/">SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!



Moving stocks this morning are earnings reports, a settlement agreement, the pricing of a public offering and more.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is rocketing close to 254% alongside heavy pre-market trading.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are soaring more than 122% with strong early morning trading.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is surging nearly 78% with heavy early morning trading today.</li>



<li>Frequency Electronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/feim-stock-quote/">FEIM</a>) shares are rising almost 33% alongside its <a href="https://www.marketwatch.com/story/frequency-electronics-shares-climb-on-higher-4q-earnings-a32189da">Q4 earnings report</a>.</li>



<li>Mammoth Energy Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/tusk-stock-quote/">TUSK</a>) stock is heading over 29% higher after <a href="https://www.nasdaq.com/press-release/cobra-acquisitions-llc-announces-settlement-agreement-prepa-2024-07-22">announcing a settlement agreement</a>.</li>



<li>ENGlobal (NASDAQ:<a href="https://investorplace.com/stock-quotes/eng-stock-quote/">ENG</a>) shares are gaining more than 22% without any clear news.</li>



<li>Wheeler Real Estate IT (NASDAQ:<a href="https://investorplace.com/stock-quotes/whlr-stock-quote/">WHLR</a>) stock is jumping over 20% with no news to report.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are climbing more than 19% despite a lack of news on Tuesday.</li>



<li>SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) stock is getting an over 15% boost on a <a href="https://www.nasdaq.com/press-release/scynexis-receive-10-million-milestone-payment-gsk-triggered-delivery-completed-furi">$10 million milestone payment</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) shares are up more than 13% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is crashing more than 59% after <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">pricing a public offering</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are plummeting close to 31% <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">after a massive rally yesterday</a>.</li>



<li>Brera (NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/">BREA</a>) stock is diving nearly 25% with strong pre-market trading this morning.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are tumbling over 22% <a href="https://www.benzinga.com/news/24/07/39892411/caremax-shares-are-up-by-more-than-200-what-you-need-to-know">after a rally yesterday</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is taking a more than 19% beating after a recent rally.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are sliding over 19% <a href="https://investorplace.com/2024/07/why-is-castellum-ctm-stock-moving-today/">alongside volatility yesterday</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling almost 16% as shares <a href="https://investorplace.com/2024/07/why-is-exicure-xcur-stock-down-27-today/">continue to come off a recent rally</a>.</li>



<li>Quoin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/">QNRX</a>) shares are dropping more than 15% today.</li>



<li>Polaris (NYSE:<a href="https://investorplace.com/stock-quotes/pii-stock-quote/">PII</a>) stock is slipping over 15% after <a href="https://www.marketwatch.com/story/polaris-stock-tumbles-11-after-earnings-fall-far-short-of-consensus-and-company-cuts-full-year-outlook-c3299335">missing earnings estimates</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares close out our pre-market stock movers down more than 14%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is down on Tuesday as the clinical-stage pharmaceutical company&rsquo;s shares come off of a major rally on Monday.



Shares of MIRA stock closed out Monday&rsquo;s normal trading hours up 627.4%. That came alongside heavy trading with <a href="https://finance.yahoo.com/quote/MIRA/">more than 153 million shares traded</a>. For comparison, its daily average trading volume is about 3.2 million shares.



Mira Pharmaceuticals stock experienced this rally after releasing data from a <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">pre-clinical study of Ketamir-2</a>. This is the company&rsquo;s novel oral ketamine analog designed to treat neurological and neuropsychiatric disorders.



The big news here is that the results were positive. This has the company excited about the prospect of furthering the development of Ketamir-2 and submitting an investigational new drug (IND) application for it.



<h2>MIRA Stock Movement on Tuesday</h2>



Considering the massive rally MIRA shares underwent yesterday, it makes sense they would give up some of those gains in the days to follow. This has the stock dropping 27.4% as of Tuesday morning.



Today&rsquo;s dip comes with more than 5.5 million shares changing hands this morning. That&rsquo;s already above its daily average trading volume but is well below yesterday&rsquo;s heavy trading.



Investors who are seeking out even more of the most recent stock market stories today will want to keep reading!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes everything happening with shares of TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock, Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>)&nbsp;stock and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-sentinelone-s-stock-amid-cybersecurity-carnage/">Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-down-27-today/">Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

MIRA Mira Pharmaceuticals files $100M mixed securities shelf

MIRA Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) just reported results for the second quarter of 2024.<ul><li>Mira Pharmaceuticals reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mira-stock-earnings-mira-pharmaceuticals-for-q2-of-2024/">MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

AMAT

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BLDP

BLUE

BREA

CARA

CATX

CMAX

COCP

CSCO

CTRM

ESPR

FEIM

GLNG

GNLN

GOEV

GOLD

GRAB

HUYA

IPDN

JAGX

KNDI

LITE

MDAI

MMAT

MNDY

NCPL

NMHI

NNDM

NUKK

OGEN

OUST

PSFE

QNRX

RDDT

RNAZ

RRAC

SACH

SAVA

SCYX

SOAR

STNE

TAYD

TCEHY

TCRT

TUSK

VUZI

WHLR

WKHS

WRNT

XXII

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Press Releases

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga